Journal Title：Targeted Oncology

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.

Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.

Current Opinion articles that place interesting areas in perspective.

Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.

Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.

Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

《靶向腫瘤學(xué)》通過提供一系列關(guān)于腫瘤學(xué)分子靶向藥物治療的文章，為致力于腫瘤學(xué)和癌癥研究的醫(yī)生和科學(xué)家提供服務(wù)。該期刊包括：

關(guān)于癌癥治療的分子靶向藥物各個(gè)方面的原創(chuàng)研究文章，包括免疫檢查點(diǎn)抑制劑和相關(guān)方法。

全面的敘述性評論文章和較短的領(lǐng)先文章，討論相關(guān)的臨床已建立的以及新興的藥物和途徑。

當(dāng)前觀點(diǎn)文章，從角度看待有趣的領(lǐng)域。

實(shí)踐中的治療文章，為病情的最佳管理提供指南，并強(qiáng)調(diào)實(shí)用的、臨床相關(guān)的考慮因素和建議。

使用 PRISMA 聲明概述的明確、系統(tǒng)方法的系統(tǒng)評價(jià)。

Adis 藥物評論，介紹腫瘤學(xué)中較新和已建立的靶向藥物的特性和治療地位。

Targeted Oncology創(chuàng)刊于2006年，由Springer International Publishing出版商出版，收稿方向涵蓋醫(yī)學(xué) - 腫瘤學(xué)全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12周，或約稿 ，影響因子指數(shù)4.4，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。